Related Experiment Video
Updated: Aug 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Lymphoblastic lymphoma in children. Poor response in advanced disease with chemotherapy for non-Hodgkin's lymphoma]
R Rivera-Luna1, R Cárdenas-Cardós, A Martínez-Avalos
1Departamento de Oncología, Instituto Nacional de Pediatría, México, D.F.
Insights
This study evaluated a chemotherapy program for pediatric lymphoblastic lymphoma (LL). While effective for early stages, the program failed in advanced disease, necessitating a revised approach similar to high-risk acute lymphoblastic leukemia protocols.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Research
Context:
- Retrospective analysis of 53 pediatric patients diagnosed with lymphoblastic lymphoma (LL) over 14 years.
- Patients' ages ranged from 1 to 16 years, with a median of 7 years.
- Clinical staging followed Murphy's system, with 51% of patients in Stage IV.
Purpose:
- To assess the efficacy of a 36-month chemotherapy program for pediatric lymphoblastic lymphoma.
- To evaluate treatment response, remission duration, and survival rates.
- To identify areas for improvement in the chemotherapy protocol for advanced disease.
Summary:
- The study analyzed 53 pediatric patients with lymphoblastic lymphoma (LL), with a significant proportion (51%) in Stage IV, often involving bone marrow and/or central nervous system (CNS).
- Of 45 evaluable patients, 31% achieved complete remission (CR) with a median duration of 66 months, while 18% abandoned treatment and 51% died.
- Actuarial survival at 11 years was 39% +/- 11%, with no relapses after 24 months in CR.
Impact:
- The current chemotherapy program is effective for early-stage LL but inadequate for advanced disease.
- There is a critical need to modify the chemotherapy protocol for advanced pediatric LL.
- Recommendations include adopting a protocol similar to that used for high-risk childhood acute lymphoblastic leukemia.
Abstract:
Fifty three pediatric patients with the histopathological diagnosis of lymphoblastic lymphoma (LL) were studied in a retrospective analysis during a 14 year period. Their age ranged from 1 to 16 years with a median of 7 years. Clinical staging was performed according to Murphy's system. There was one child in stage I (2%), 11 in stage II (21%), 14 stage III (26%) and 27 stage IV (51%). Patients in stage IV, 21 (78%) had initial bone marrow involvement, 4 (15%) central nervous system (CNS) infiltration and 2 (7%) simultaneous infiltration to the bone marrow and the CNS. The chemotherapy program consisted of induction, consolidation and maintenance with CNS prophylaxis. The whole program lasted 36 months. Out of 53 patients there were only 45 evaluable for treatment analysis response. A total of 14 (31%) are alive and in a continuous complete remission, with a median duration of remission of 66 months, 8 (18%) children abandoned treatment with a median duration of remission of 10 months. Twenty three patients (51%) are dead. The actuarial survival at 11 year is of 39% +/- 11% with a median remission rate for the whole group of 11.8 months. No patient in complete remission for more than 24 months has relapsed. We conclude that our chemotherapy program is more than adequate for early stages, but for advanced disease it has been a failure. There is a need to modify the chemotherapy program using a very similar protocol as the one used in high risk childhood acute lymphoblastic leukemia.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

